<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty patients (age range, 4 to 48 years; median age, 36 years) with de novo or drug-induced <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> or <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> were treated with myeloablative immunosuppressive therapy followed by bone marrow transplantation (BMT) </plain></SENT>
<SENT sid="1" pm="."><plain>Four preparative regimens were used; three regimens consisted of combined total body irradiation (TBI) and chemotherapy and one of combination chemotherapy only </plain></SENT>
<SENT sid="2" pm="."><plain>One patient received marrow from his identical twin brother, whereas the other 19 patients were grafted with marrow from histocompatible siblings </plain></SENT>
<SENT sid="3" pm="."><plain>In 19 patients the abnormal clone was at least temporarily ablated, while in one patient the congenital <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> persisted </plain></SENT>
<SENT sid="4" pm="."><plain>Eight patients are alive and well for +108 to +3,359 days post-transplantation </plain></SENT>
<SENT sid="5" pm="."><plain>Nine patients died of transplant-related complications (six of interstitial <z:hpo ids='HP_0002090'>pneumonia</z:hpo>, two of <z:hpo ids='HP_0002239'>gastrointestinal bleeding</z:hpo>, and one of fungal <z:hpo ids='HP_0100806'>sepsis</z:hpo>) and three patients died with persisting or recurring disease </plain></SENT>
<SENT sid="6" pm="."><plain>One patient with a late recurrence has undergone a second successful bone marrow transplant procedure </plain></SENT>
<SENT sid="7" pm="."><plain>Outcome of BMT was not related to French-American-British (FAB) type, marrow <z:mp ids='MP_0003045'>fibrosis</z:mp>, cytogenetic abnormalities, or preparation regimen </plain></SENT>
<SENT sid="8" pm="."><plain>Marrow transplantation as a means of providing long-term disease-free survival and possible cure should be considered in patients if a suitable donor is available </plain></SENT>
</text></document>